The battle over who should provide obesity and diabetes drugs like Ozempic and Wegovy has reached a critical point, as manufacturers and compounding pharmacies clash over the demand of these medications, NPR reported Nov. 20.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
